These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 33178841)

  • 1. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
    Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
    J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.
    Joshi M; Ansell SM
    J Immunol Res; 2020; 2020():8820377. PubMed ID: 33294467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.
    Barroso-Sousa R; Tolaney SM
    Curr Treat Options Oncol; 2020 Jun; 21(7):59. PubMed ID: 32556894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials.
    Akhbariyoon H; Azizpour Y; Esfahani MF; Firoozabad MSM; Rad MR; Esfahani KS; Khoshavi N; Karimi N; Shirinisaz A; Abedi F; Rad MR; Sharifi P
    Clin Immunol; 2021 Nov; 232():108873. PubMed ID: 34688855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
    Hu B; Jacobs R; Ghosh N
    Curr Hematol Malig Rep; 2018 Dec; 13(6):543-554. PubMed ID: 30338457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art.
    Zanelli M; Fragliasso V; Parente P; Bisagni A; Sanguedolce F; Zizzo M; Broggi G; Ricci S; Palicelli A; Foroni M; Gozzi F; Gentile P; Morini A; Koufopoulos N; Caltabiano R; Cimino L; Fabozzi M; Cavazza A; Neri A; Ascani S
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
    Gravelle P; Burroni B; Péricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; Fournié JJ; Laurent C
    Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutual exclusivity and co-occurrence patterns of immune checkpoints indicate NKG2A relates to anti-PD-1 resistance in gastric cancer.
    Li G; Liu X; Gu C; Ma G; Li S; Ma Z; Xiong Y; Jiang Y; Huang Q; Wu J; Wu Z; Liao W; Wu Q; Shi M
    J Transl Med; 2024 Aug; 22(1):718. PubMed ID: 39097734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically Engineered Mouse Models Support a Major Role of Immune Checkpoint-Dependent Immunosurveillance Escape in B-Cell Lymphomas.
    Lemasson Q; Akil H; Feuillard J; Vincent-Fabert C
    Front Immunol; 2021; 12():669964. PubMed ID: 34113345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.
    Lurain K; Ramaswami R; Mangusan R; Widell A; Ekwede I; George J; Ambinder R; Cheever M; Gulley JL; Goncalves PH; Wang HW; Uldrick TS; Yarchoan R
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer.
    Dermime S; Merhi M; Merghoub T
    Front Immunol; 2021; 12():781872. PubMed ID: 34745152
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
    Zhang Q; Tang L; Zhou Y; He W; Li W
    Front Immunol; 2021; 12():663986. PubMed ID: 34122422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas.
    Ribatti D; Cazzato G; Tamma R; Annese T; Ingravallo G; Specchia G
    Front Oncol; 2024; 14():1420920. PubMed ID: 39091917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.
    Landsburg DJ; Koike A; Nasta SD; Svoboda J; Schuster SJ; Wasik MA; Caponetti GC
    Cancer Immunol Immunother; 2021 Mar; 70(3):869-874. PubMed ID: 32857184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.